At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
Romidepsin +1 moredrug
Likely dose
Romidepsin 14 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Rifampin on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating Romidepsin and Rifampin for Hematologic Malignancy and Malignant Lymphoma. Completed, enrolled 14 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancy, Malignant Lymphoma
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartApr 2011
Primary CompletionFeb 2012
Study CompletionMar 2012
TodayJul 2026
First PostedMar 29, 2011
Enrollment StartApr 1, 2011
Primary CompletionFeb 1, 2012
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.3 years ago
Interventions
Romidepsindrug
14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
Rifampindrug
600 mg oral once daily on Days 4-8